VBIVinactive

VBI VACCINES INC/BC

Healthcare·Oncology·Commercial

OncologyImmunologyInfectious Disease

VBI VACCINES INC/BC (VBIV): 9 pipeline candidates · 3 clinical trials. Updated within the last hour.

10.0/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health10.0

0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth10.0

9 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for VBI VACCINES INC/BCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

—

Quarterly Burn

$11.8M

Runway

—

Revenue

$1.2M

Pipeline (9 candidates)

Drug	Phase	Indication
lomustine	Phase 1/Phase 2	Glioblastoma Multiforme
prehevbrio	Approved	Prevention of infection caused by all known subtypes of HBV ...
vbi-1501	Phase 1/Phase 2	Cytomegalovirus (CMV)
vbi-1901	Phase 1/Phase 2	Glioblastoma Multiforme
vbi-2601	Phase 2	Hepatitis B
vbi-2901	Phase 1/Phase 2	COVID-19
vbi-2901a	Phase 1	COVID-19
vbi-2902	Phase 1/Phase 2	COVID-19 (Ancestral)
vbi-2905	Phase 1/Phase 2	COVID-19 (Beta variant)

3 clinical trials·CEO: Jeffrey R. Baxter

Frequently asked questions

How many drug candidates are in VBI VACCINES INC/BC's pipeline?

VBI VACCINES INC/BC (VBIV) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is VBI VACCINES INC/BC's lead drug candidate?

VBI VACCINES INC/BC's most advanced tracked candidate is lomustine (Phase 1/Phase 2) for Glioblastoma Multiforme.

Who is the CEO of VBI VACCINES INC/BC?

Jeffrey R. Baxter is the chief executive officer of VBI VACCINES INC/BC (VBIV).

Get the full picture on VBI VACCINES INC/BC

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free Analysis Browse Calendar